ARCHIVES

FDA Advisors Unanimously Turn Down GPC Biotech’s Orplatna for Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 29 | July 27, 2007

Download PDF Visit The Full Archive

Related Articles

ASBMT Installs New Officers

March 14, 2003

New HIP Analysis Supports Mammography Screening Ages 40-49

September 23, 1988

Pinkel Corrects Report On ALL – Two Drugs Are Better Than One

April 21, 1978

In Brief: NCFA Offers Grants For Research On Impact Of DRGs; ACCC Leaders Dispute HCFA Chief

March 8, 1985

Amgen Claimed QOL Benefit Despite FDA Label Change.

May 18, 2007

In Brief: Ingell Vows To Broaden Indirect Cost Inquiry; Gallo, Fauci Make ‘Most Prolific Scientist’ List

February 7, 1992